Cantitate/Preț
Produs

Risk-Benefit Analysis in Drug Research: Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980

Editat de J.F. Cavalla
en Limba Engleză Paperback – 4 aug 2012
The appreciation of risk like the awareness of beauty lies very much in the eyes of the beholder. It involves a value judgement and can never be absolute. Yet paradoxically, modern society is demanding ever greater degrees of safety in the medicines it takes, to the extent that nothing short of the total absence of risk will be tolerated. Since 1960, and mainly as a result of the thalidomide tragedy, governmental regulation of testing and use of new medicines has grown apace throughout the world. It has derived impetus not only from the understandable wish of the public to seek protection, but also from the anxiety of bureaucrats and politicians not to be seen to have made mistakes. Both these concerns have been inflamed by the recognition of the media that all drugs make news and horror drugs make the best news of all. Prior to this time the physician and his cures enjoyed a relatively supportive public. It was true that quacks existed and were recognized as such but, in the main, people wanted to take medicines and expected them to do them good.
Citește tot Restrânge

Preț: 34584 lei

Preț vechi: 36405 lei
-5% Nou

Puncte Express: 519

Preț estimativ în valută:
6619 7028$ 5483£

Carte tipărită la comandă

Livrare economică 25 decembrie 24 - 08 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9789401571340
ISBN-10: 9401571341
Pagini: 208
Ilustrații: 197 p. 7 illus.
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.3 kg
Ediția:Softcover reprint of the original 1st ed. 1981
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands

Public țintă

Research

Cuprins

1 Risk—benefit in medicine.- 2 The effect on industry.- 3 The effect on the public.- Discussion of Chapters 2 and 3.- 4 The necessary role of government.- 5 Problems facing a regulatory authority.- Discussion of Chapters 4 and 5.- 6 The effect on pharmaceutical research.- 7 New-drug assessment in man: a clinical pharmacologist’s view.- Discussion of Chapters 6 and 7.- 8 The effect on choice of research.- 9 The relative worth of animal testing.- 10 The prospect of product liability.- Discussion of Chapters 9 and 10.- 11 The effect on world medicine.- 12 Preclinical requirements.- 13 Post-marketing drug surveillance.- Discussion of Chapters 12 and 13.- 14 The influence of the media.- Discussion of Chapter 14.- 15 The influence of the medical profession.- Summary and conclusions.